First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer-Reference-Cited by-全球学者库

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Published:2016-05-25 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Greenhalgh Janette¹,Dwan Kerry²,Boland Angela¹,Bates Victoria¹,Vecchio Fabio¹,Dundar Yenal¹,Jain Pooja³,Green John A⁴

Affiliation:

1. University of Liverpool; Liverpool Reviews and Implementation Group; Sherrington Building Ashton Street Liverpool UK L69 3GE

2. Cochrane Central Executive; St Albans House, 57-59 Haymarket London England UK SW1Y 4QX

3. Clatterbridge Cancer Centre; Clatterbridge Road Bebington Merseyside UK CH63 4JY

4. University of Liverpool; Institute of Translational Medicine; Clatterbridge Cancer Centre Clatterbridge Road Bebington Merseyside UK CH63 4JY

Publisher

Wiley

Subject

Pharmacology (medical)

Reference135 articles.

1. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer;Khambata-Ford;Journal of Clinical Oncology,2010

2. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;Journal of Clinical Oncology,2010

3. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older;Chen;Journal of Thoracic Oncology,2012

4. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Annals of Oncology,2015

5. Quality of life (QOL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin in Asian patients with epidermal growth factor receptor (EGFR) mutation positive (MUT+) non-small cell lung cancer (NSCLC);Wu;Journal of Thoracic Oncology,2014

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of miR‐578 through SOCS2‐dependent manner reverses gefitinib resistance in NSCLC cells;Environmental Toxicology;2023-11-10

2. Invasive Diagnostic Procedures from Bronchoscopy to Surgical Biopsy—Optimization of Non-Small Cell Lung Cancer Samples for Molecular Testing;Medicina;2023-09-27

3. Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial;Thoracic Cancer;2023-09-12

4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells;Modern Pathology;2023-09

5. Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting;Cancer Medicine;2023-06